Cilostazol and Nimodipine Combined Therapy After Aneurysmal Subarachnoid Hemorrhage (aSAH)

Stopped early · Phase 4 · Has a placebo group

Conditions studied: Aneurysmal Subarachnoid Hemorrhage

In brief

The investigators seek to demonstrate that the combined use of cilostazol and nimodipine will significantly decrease the rate of delayed cerebral infarction and cerebral vasospasm after cerebrovascular intervention when compared to nimodipine alone.

Key facts

Study ID

NCT04148105

Run by

Henry Ford Health System

People needed

19

Starts

2019-11-01

Expected to finish

2023-05-26

Last updated by the study team

2024-05-31

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age or older
• Anterior circulation aneurysm
• Patients who have undergone surgical intervention
• Absence of rebleeding or new intracranial hemorrhage noted on post-intervention CT scan
• Consent for study participation

You may not qualify if…

• Non-aneurysmal subarachnoid hemorrhage
• Multiple ruptured aneurysms
• Patients with congestive heart failure
• Severe aneurysmal subarachnoid hemorrhage (Hunt Hess Grade V)
• Active pathological bleeding
• Allergy to cilostazol
• Positive pregnancy test
• Coagulopathy not caused by anti-coagulant use
• History of hemorrhagic complications (gastrointestinal bleeding, etc)
• Uncontrolled or severe comorbidity that would qualify as an absolute contraindication for cilostazol
• Patients requiring anticoagulant/antiplatelet treatment following intervention (e.g. stent-assisted coiling or flow-diverting stent obliteration of aneurysm)

Where it is running

• Ascension Providence Hospital — Southfield, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.